PD-L1、miR-29a、miR let-7a对三阴性乳腺癌患者预后的评估价值分析  

Evaluation Value of PD-L1,miR-29a,miR let-7a in the Prognosis of Triple Negative Breast Cancer Patients

作　　者：付梦婷 段馨[1] 颜佳 李雨昂 FU Mengting;DUAN Xin;YAN Jia(The First Affiliated Hospital of Zhengzhou University,Zhengzhou,450000)

机构地区：[1]郑州大学第一附属医院,450000

出　　处：《实用癌症杂志》2024年第5期726-729,共4页The Practical Journal of Cancer

摘　　要：目的探讨程序性死亡蛋白配体-1(PD-L1)、微小RNA-29a(miR-29a)、微小RNA let-7a(miR let-7a)在三阴性乳腺癌(TNBC)患者预后评估中的临床价值。方法将67例TNBC患者作为观察组,同期收治的67例乳腺良性肿物患者作为对照组。所有患者均采集标本送检,测定PD-L1表达水平,并采集5 ml空腹静脉血,采用实时荧光定量PCR法测定miR-29a、miR let-7a表达情况,分析PD-L1、miR-29a、miR let-7a与其临床病理特征及预后的关系。结果观察组PD-L1阳性率、miR-29a表达量、miR let-7a表达量高于对照组,PD-L1阳性组临床分期Ⅲ期、淋巴结转移率高于PD-L1阴性组,临床分期Ⅲ期、淋巴结转移患者miR-29a、miR let-7a表达水平高于临床分期Ⅰ~Ⅱ期、无淋巴结转移患者,差异有统计学意义(P<0.05);67例患者随访3年后存活率为59.70%(40/67);PD-L1阳性患者存活率低于PD-L1阴性患者,存活者miR-29a、miR let-7a表达水平低于死亡组,差异有统计学意义(P<0.05)。结论PD-L1、miR-29a、miR let-7a在TNBC中呈高表达,与临床分期、淋巴结转移关系密切,且高表达患者存活率更低,可作为临床评估预后的重要指标。Objective To investigate the clinical value of programmed death protein ligand-1(PD-L1),microRNA-29a(miR-29a),microRNA let-7a(miR let-7a)in the prognosis evaluation of triple negative breast cancer(TNBC)patients.Methods 67 patients with TNBC were selected as the observation group,while 67 patients with benign breast tumors admitted during the same period were selected as the control group.All patients were collected and tested for PD-L1 expression levels,and 5 ml of fasting venous blood was collected.Real time fluorescence quantitative PCR was used to measure the expression of miR-29a and miR let-7a,and the relationship between PD-L1,miR-29a,and miR let-7a and their clinical pathological characteristics and prognosis was analyzed.Results That the PD-L1 positive rate,miR-29a expression level,and miR let-7a expression level in the observation group were higher than those in the control group.The clinical stage Ⅲ and lymph node metastasis rate in the PD-L1 positive group were higher than those in the PD-L1 negative group.The expression levels of miR-29a and miR let-7a in clinical stage Ⅲ and lymph node metastasis patients were higher than those in clinical stage Ⅰ~Ⅱ and patients without lymph node metastasis,and the difference was statistically significant(P<0.05);After a 3-year follow-up,the survival rate of 67 patients was 59.70%(40/67);The survival rate of PD-L1 positive patients was lower than that of PD-L1 negative patients,and the expression levels of miR-29a and miR let-7a in survivors were lower than those in the death group,with statistically significant differences(P<0.05).Conclusion PD-L1,miR-29a,and miR let-7a are highly expressed in TNBC,closely related to clinical staging and lymph node metastasis.Patients with high expression have a lower survival rate,and can be used as important prognostic indicators for clinical evaluation.

关 键 词：三阴性乳腺癌 程序性死亡蛋白配体-1 病理特征 预后 临床价值 

分 类 号：R737.9[医药卫生—肿瘤]